204 results on '"Cristescu R"'
Search Results
2. How microbiomes can help inform conservation: landscape characterisation of gut microbiota helps shed light on additional population structure in a specialist folivore
3. Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma
4. Antimicrobial polycaprolactone/polyethylene glycol embedded lysozyme coatings of Ti implants for osteoblast functional properties in tissue engineering
5. Microbial colonization of biopolymeric thin films containing natural compounds and antibiotics fabricated by MAPLE
6. 190MO Association of 18-Gene expression profile (GEP) with clinical outcomes in patients with metastatic triple-negative breast cancer (mTNBC) treated with pembrolizumab (Pembro) or chemotherapy (Chemo) in KEYNOTE-119
7. Pulsed Laser Processing of Functionalized Polysaccharides for Controlled Release Drug Delivery Systems : Functionalized Polysaccharides Processed for Drug Delivery
8. Evaluating the genetic consequences of population subdivision as it unfolds and how to best mitigate them: A rare story about koalas.
9. Antimicrobial activity of biopolymer–antibiotic thin films fabricated by advanced pulsed laser methods
10. Functionalized porphyrin conjugate thin films deposited by matrix assisted pulsed laser evaporation
11. North Stradbroke Island: An Island ark for Queensland's koala population?
12. Magnetic core/shell nanoparticle thin films deposited by MAPLE: Investigation by chemical, morphological and in vitro biological assays
13. MAPLE deposition of Mn(III) metalloporphyrin thin films: Structural, topographical and electrochemical investigations
14. Deposition of antibacterial of poly(1,3-bis-(p-carboxyphenoxy propane)-co-(sebacic anhydride)) 20:80/gentamicin sulfate composite coatings by MAPLE
15. Functional porphyrin thin films deposited by matrix assisted pulsed laser evaporation
16. Functional polyethylene glycol derivatives nanostructured thin films synthesized by matrix-assisted pulsed laser evaporation
17. Thin films of polymer mimics of cross-linking mussel adhesive proteins deposited by matrix assisted pulsed laser evaporation
18. Laser processing of polyethylene glycol derivative and block copolymer thin films
19. Functionalized polyvinyl alcohol derivatives thin films for controlled drug release and targeting systems: MAPLE deposition and morphological, chemical and in vitro characterization
20. Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase 3 trial in patients with gastroesophageal adenocarcinoma
21. Matrix-assisted pulsed laser methods for biofabrication
22. MAPLE applications in studying organic thin films
23. Polycaprolactone biopolymer thin films obtained by matrix assisted pulsed laser evaporation
24. Processing of poly(1,3-bis-( p-carboxyphenoxy propane)- co-(sebacic anhydride)) 20:80 (P(CPP:SA)20:80) by matrix-assisted pulsed laser evaporation for drug delivery systems
25. Deposition of biopolymer thin films by matrix assisted pulsed laser evaporation
26. Laser deposition of cryoglobulin blood proteins thin films by matrix assisted pulsed laser evaporation
27. Matrix assisted pulsed laser evaporation processing of triacetate-pullulan polysaccharide thin films for drug delivery systems
28. A Comparison Between Cone Beam-Computed Tomography and Ex Vivo Measurement of the Working Length: OR 58
29. Processing of mussel-adhesive protein analog copolymer thin films by matrix-assisted pulsed laser evaporation
30. Laser deposition of fibrinogen blood proteins thin films by matrix assisted pulsed laser evaporation
31. Processing of mussel adhesive protein analog thin films by matrix assisted pulsed laser evaporation
32. New results in pulsed laser deposition of poly-methyl-methacrylate thin films
33. Laser Thin Film Processing of Biopolymers: Mussel Adhesive Protein Analog
34. 1416P Genomic landscape of late-stage gastric cancer
35. 1048P Baseline and post-treatment biomarkers of resistance to anti-PD-1 (aPD1) therapy in acral and mucosal melanoma
36. 789P PD-L1 and tumor mutational burden (TMB) in standard-of-care (SOC): Treated advanced cervical cancer
37. 796P Association between biomarkers and clinical outcomes of lenvatinib (L) + pembrolizumab (P) in advanced endometrial cancer (EC): Results from KEYNOTE-146/study 111
38. 61MO Biomarker analysis of men with enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) + enza in KEYNOTE-199
39. Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab
40. 1442P Association of TMB using the Foundation Medicine Companion Diagnostic (F1CDx) with efficacy of first-line pembrolizumab (pembro) or pembro plus chemotherapy (pembro + chemo) versus chemo in patients with gastric cancer (gc) from KEYNOTE-062
41. 747P Association of TMB with efficacy of pembrolizumab (pembro) in patients (pts) with advanced urothelial cancer (UC): Results from KEYNOTE-045 and KEYNOTE-052
42. LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042
43. LBA5 - KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC
44. Environmental impact assessments can misrepresent species distributions: a case study of koalas in Queensland, Australia.
45. LBA80 - Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407
46. LBA79 - Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials
47. OA04.05 KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC
48. OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC
49. LBA36 - Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study
50. 99P - A novel framework for evaluating biomarker response relationships in immuno-oncology (IO)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.